moderate acne vulgaris Silver nanoparticle 2.5% Benzoyl peroxide Clindamycin Acne vulgaris
Conditions
Interventions
24 ppm silver nanoparticle gel use twice daily
and
2.5% benzoyl peroxide use twice daily ,1% clindamycin gel use twice daily
and
2.5% benzoyl peroxide use twice daily
Experimental Drug,Active Comparator Drug
Silver nanoparticle + 2.5% benzoyl peroxide,Clindamycin + 2.5% benzoyl peroxide
Sponsors
Faculty of Medicine, Srinakharinwirot University
Faculty of Medicine,
Srinakharinwirot University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: The patients aged over 18 years old with moderate acne vulgaris by the Leeds-revised criteria with voluntarily signed with informed consent
Exclusion criteria
Exclusion criteria: 1. Patients who previously applied topical corticosteroids, silver-containing drug, topical erythromycin, topical clindamycin, benzoyl peroxide, topical retinoids, chemical peels, topical vitamin C and E within two weeks prior to the study 2. Patients who took oral supplementation (oral zinc, vitamin C, vitamin E), oral antibiotics, oral corticosteroids within six weeks prior to study and oral retinoids within six months prior to study 3. Patients who were allergic to silver-containing drug, benzoyl peroxide and topical clindamycin 4. Currently pregnant and lactating women 5. Active skin lesion on study site 6. Unable to follow-up according to the study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy 8 weeks lesion counts | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety 8 weeks Safety evaluation | — |
Countries
Thailand
Contacts
Public ContactNatthachat Jurairattanaporn
Faculty of Medicine, Srinakharinwirot University
Outcome results
None listed